Chargement...

Robocath in a few words

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer, thanks to reliable technologies, while complementing manual interventions.
R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. It is designed to operate with precision and perform specific movements creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all.

History

2009
Company foundation
2013
First in vivo tests
2014
ISO 13485 certification granted
2015
Industrial prototype
2017
Safety-Efficacy study
2019
R-One pre-launch

Robocath in the world

19 Rue Marie Curie, Rouen, France
50 Milk Street, Boston, Massachusetts, États-Unis

Management

Philippe BENCTEUX

Founder & President
Learn more
A doctor of medicine and a graduate of the 'Healthcare Industry Strategy and Management' program at ESSEC Business School, Philippe Bencteux has over twenty years of experience in vascular imaging. A trained neuro-radiologist, he founded Robocath in 2009 on the basis of the promising preliminary research carried out in collaboration with two engineering schools. He has since contributed his expertise in the medical sector to the company and is actively involved in the conception of new robotics solutions.

Lucien GOFFART

CEO
Learn more
Holding a master’s degree in Business, Lucien Goffart started his career in 1999 at Johnson & Johnson Inc. Then, he joined Abbott before holding different positions at Volcano company between 2004 and 2011. From 2012 to 2014, he held different executive positions at Stentys and Mitralgin. Last four years, he served Boston Scientific as Business Unit Manager France. In the meanwhile, he was Board member of several companies from the Medtech industry such as Opsens Medical. Since 2019, he is Board member of Electroducer and was appointed CEO of Robocath in September.

Bruno FOURNIER

CTO
Learn more
Bruno Fournier is a trained engineer (Supélec) and Doctor of Science (Université Paris VI), with strong R&D experience in the healthcare sector. He led the development of products with high added value in several fields (ultrasound, bone density measurement, respiratory support, etc.). Passionate about new medical technologies, he joined Robocath in 2012 after management roles with the Air Liquide Groupe and his time as Director of R&D at one of Getinge Group subsidiary from 2006 to 2012.

Dominique DESTRIEZ

CFO
Learn more
Graduated from HEC and holding a Phd in accountancy, Dominique DESTRIEZ started his career in international audit and management accounting within large companies afterwards. He then joined Nocibé, a french comestic group, as financial director and played an active role in the company’s growth from 1999 to 2004. For over 15 years, Dominique supports investment funds and their participations to achieve financial structuring, M&A, funds raising, international development and stock exchange listing.

Strategic Committee

Alexandre SCHERER

M CAPITAL
Learn more
M Capital Partners is an independent and entrepreneurial French investment and financing company. It took a stake in Robocath in 2017.

Pierre-Emmanuel STRUYVEN

SUPERNOVA INVEST
Learn more
Newly created by the CEA Investissement seasoned funds management team, CEA and Amundi, Supernova Invest is specialized in deep-tech venture capital in life sciences, energy and industry (electronics, advanced materials, instruments…).

François GUISSET

NORMANDIE PARTICIPATIONS
Learn more
Normandie Participations, an equity financing tool backed by AD Normandie, is a regional financing structure for equity participations in companies based in Normandy. The fund took a stake in Robocath in 2017.

Jean-Marc BUCHET

NCI
Learn more
An historic investor in Robocath (since 2013), NCI is a major player in capital investment in Normandy.

Bruno GUICHEUX

GO CAPITAL
Learn more
An historic investor in Robocath (since 2013), GO CAPITAL is an investment fund management company that favors companies with high growth potential in the fields of healthcare, technology (hardware and software), digital and innovative services.

Medical Advisory Board

Professeur A. CRIBIER

Former Chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI
Learn more
Professor of medicine and former chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI (Transcatheter Aortic Valve Implantation) procedure, a breakthrough, less invasive interventional treatment for structural heart diseases. Since its creation, the device has been implanted in thousands of patients around the world. He is the author of more than 600 publications and has received several major international medical and scientific awards.

Docteur J. FAJADET

Co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse (France), co-director of EuroPCR congress
Learn more
• co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.

Docteur A. CREMONESI

Head of the Villa Maria hospital cardiovascular department in Bologna (Italy) and active member of EuroPCR Board
Learn more
Head of the Villa Maria hospital cardiovascular department in Bologna (Italy) for the last 25 years, published many interventional cardiology and peripheral vascular papers. From 2011 to 2013, he was president of the Italian society of interventional cardiology. He has for many years been an active member of the PCR board and received several awards in recognition of his achievements.

Professeur G. STONE

Director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation
Learn more
professor of medicine and director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation, both in New York. Regularly engaged in clinical research and professional education, he has led and published more than 2,000 manuscripts and abstracts and has received several major awards for his work. He is director of the TCT Congress (Transcatheter Cardiovascular Therapeutics), one of the largest interventional cardiology gatherings in the world.

Professor E. DURAND

Rouen University Hospital
Learn more

Professor R. SABATIER

Caen University Hospital
Learn more

Professor M. HAUDE

Neuss Clinic - Neuss Germany
Learn more
Pr. Haude has been head physician of the Medical Clinic I at the Clinic Neuss for 13 years and is thus also in charge of cardiology and of their cardiac catheter labs. In addition, Professor Haude has been involved in interventional cardiology for 31 years and has been past chairman of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology , PCR and ESC board member and EAPCI president from 2016 to 2018. He currently is an EAPCI board member, Pr. Haude has published more than 300 scientific articles.

Doctor F. LORGAT

Netcare Christiaan Barnard Memorial Hospital - Cape Town, South Africa
Learn more
Dr. Lorgat is an interventional cardiologist at Christiaan Barnard Memorial Hospital since 1998. As one of the first users of a robotic system for electrophysiology, Dr. Lorgat has performed more than 1,600 procedures with this robotic assistance over a period of 6 years and is an active research contributor in this field.

Awards

Rated as fourth Medical French Start-up
by Forbes Magazine
Winner of the TechInnov Award 2015
Nominee for "Trophée de l'Avenir" 2018
by Europe 1
Nominee for French Start-up of the year 2018
by EY

Partners